How many drugs treat Obsessive-compulsive disorder?

Drug Landscape tracks 5 marketed treatments for Obsessive-compulsive disorder (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/obsessive-compulsive-disorder.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Obsessive-compulsive disorder — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Obsessive-compulsive disorder (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Obsessive-compulsive disorder, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zoloft	sertraline	Pfizer Inc.	SSRI (Selective serotonin reuptake inhibitor)	Cytochrome P450 2C19, Melanocortin receptor 5, 5-hydroxytryptamine receptor 2A	1991-12-30
Anafranil	CLOMIPRAMINE	Specgx Llc	Tricyclic Antidepressant	Sodium-dependent serotonin transporter	1989-01-01
Prozac	fluoxetine	Eli Lilly and Company	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin reuptake transporter	1987-12-29
Sertralin	Sertralin	Poznan University of Medical Sciences		Cytochrome P450 2C19, Melanocortin receptor 5, 5-hydroxytryptamine receptor 2A
Prozac	Prozac	RenJi Hospital		Equilibrative nucleoside transporter 4, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Obsessive-compulsive disorder
Eli Lilly and Company · 1 drug in Obsessive-compulsive disorder
Pfizer Inc. · 1 drug in Obsessive-compulsive disorder
Poznan University of Medical Sciences · 1 drug in Obsessive-compulsive disorder
RenJi Hospital · 1 drug in Obsessive-compulsive disorder
Specgx Llc · 1 drug in Obsessive-compulsive disorder

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Obsessive-compulsive disorder:

Cite this brief

Drug Landscape (2026). Obsessive-compulsive disorder — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/obsessive-compulsive-disorder. Accessed 2026-06-10.

Obsessive-compulsive disorder full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing